Literature DB >> 25711737

Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma: an open question.

Jacopo Giuliani1, Andrea Bonetti2.   

Abstract

Entities:  

Year:  2015        PMID： 25711737     DOI： 10.1007/s00405-015-3562-4

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN： 0937-4477            Impact factor:   2.503


× No keyword cloud information.
  18 in total

Review 1.  Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck.

Authors:  Adrian R Levy; Karissa M Johnston; Jennifer Sambrook; Bonnie Donato; John R Penrod; Mitra Corral; Martin Chasen
Journal:  Curr Med Res Opin       Date:  2011-11-14       Impact factor: 2.580

2.  Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?

Authors:  Nadeem Riaz; Eric J Sherman; Matthew Fury; Nancy Lee
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

3.  Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.

Authors:  David G Pfister; Yungpo Bernard Su; Dennis H Kraus; Suzanne L Wolden; Eric Lis; Timothy B Aliff; Andrew J Zahalsky; Simone Lake; Michael N Needle; Ashok R Shaha; Jatin P Shah; Michael J Zelefsky
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 5.  Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.

Authors:  James E Frampton
Journal:  Drugs       Date:  2010-10-22       Impact factor: 9.546

6.  Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).

Authors:  Lorraine Walsh; Charles Gillham; Mary Dunne; Ian Fraser; Donal Hollywood; John Armstrong; Pierre Thirion
Journal:  Radiother Oncol       Date:  2010-12-13       Impact factor: 6.280

Review 7.  The role of cetuximab in the management of head and neck cancers.

Authors:  Peyman Kabolizadeh; Gregory J Kubicek; Dwight E Heron; Robert L Ferris; Michael K Gibson
Journal:  Expert Opin Biol Ther       Date:  2012-04       Impact factor: 4.388

8.  Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma.

Authors:  Jessica Ley; Paul Mehan; Tanya M Wildes; Wade Thorstad; Hiram A Gay; Loren Michel; Brian Nussenbaum; Kathryn Trinkaus; Douglas Adkins
Journal:  Oncology       Date:  2013-11-06       Impact factor: 2.935

9.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

10.  Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment.

Authors:  Jimmy J Caudell; Stephen M Sawrie; Sharon A Spencer; Renee A Desmond; William R Carroll; Glenn E Peters; Lisle M Nabell; Ruby F Meredith; James A Bonner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-20       Impact factor: 7.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.